• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Would pan-tuberculosis treatment regimens be cost-effective?泛结核病治疗方案是否具有成本效益？
Lancet Respir Med. 2018 Jul;6(7):486-488. doi: 10.1016/S2213-2600(18)30197-8. Epub 2018 May 31.
2
Management of latent tuberculosis infection in immigrants.移民中潜伏性结核感染的管理
N Engl J Med. 2003 Mar 27;348(13):1289-92; author reply 1289-92.
3
$ 1.4 billion funding shortfall for tuberculosis control.结核病防治资金缺口达14亿美元。
Lancet Infect Dis. 2013 Dec;13(12):1016-7. doi: 10.1016/s1473-3099(13)70350-5.
4
A roadmap for new tuberculosis drugs.新型结核病药物研发路线图。
Lancet. 2007 May 26;369(9575):1764. doi: 10.1016/S0140-6736(07)60790-9.
5
Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria.埃及和叙利亚不同结核病治疗策略的成本效益
Int J Tuberc Lung Dis. 2002 Dec;6(12):1083-90.
6
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.一种泛结核病治疗方案的预期健康和经济影响：建模研究。
Lancet Glob Health. 2024 Oct;12(10):e1629-e1637. doi: 10.1016/S2214-109X(24)00284-5. Epub 2024 Aug 16.
7
Tuberculosis: where are we going?结核病：我们将何去何从？
Clin Med (Lond). 2007 Jan-Feb;7(1):90. doi: 10.7861/clinmedicine.7-1-90.
8
Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.三种高负担国家新型结核病治疗方案的经济学影响：建模分析。
Lancet Glob Health. 2024 Jun;12(6):e995-e1004. doi: 10.1016/S2214-109X(24)00088-3.
9
Shorter drug regimens for tuberculosis: the multiple applications of decision models.结核病的短程药物治疗方案：决策模型的多种应用
Int J Tuberc Lung Dis. 2013 May;17(5):569. doi: 10.5588/ijtld.13.0204.
10
The economic divide and tuberculosis. Tuberculosis is not just a medical problem, but also a problem of social inequality and poverty.经济鸿沟与结核病。结核病不仅是一个医学问题，也是社会不平等和贫困问题。
EMBO Rep. 2003 Jun;4 Spec No(Suppl 1):S24-8. doi: 10.1038/sj.embor.embor842.

引用本文的文献

1
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.一种泛结核病治疗方案的预期健康和经济影响：建模研究。
Lancet Glob Health. 2024 Oct;12(10):e1629-e1637. doi: 10.1016/S2214-109X(24)00284-5. Epub 2024 Aug 16.
2
Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?在当前新冠疫情时代，泛结核病短程治疗方案能否成为印度到2025年终结结核病的希望之光？
Indian J Tuberc. 2022 Oct;69(4):377-382. doi: 10.1016/j.ijtb.2022.06.006. Epub 2022 Jun 23.
3
Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis.衡量耻辱感以评估与健康相关政策决策的社会正义影响：在耐多药结核病新型治疗方案中的应用
MDM Policy Pract. 2020 Apr 26;5(1):2381468320915239. doi: 10.1177/2381468320915239. eCollection 2020 Jan-Jun.
4
The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.在印度推广泛结核病药物方案的可能性：建模分析。
PLoS One. 2020 Mar 27;15(3):e0230808. doi: 10.1371/journal.pone.0230808. eCollection 2020.
5
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.评估一种新型抗结核治疗方案的影响：基于预测患者结局和流行病学考虑的建模分析。
BMC Infect Dis. 2019 Sep 9;19(1):794. doi: 10.1186/s12879-019-4429-x.

本文引用的文献

1
Pan-tuberculosis regimens: an argument against.泛结核病治疗方案：反对的观点
Lancet Respir Med. 2018 Apr;6(4):240-242. doi: 10.1016/S2213-2600(18)30097-3.
2
Pan-tuberculosis regimens: an argument for.全结核病治疗方案：支持的理由
Lancet Respir Med. 2018 Apr;6(4):239-240. doi: 10.1016/S2213-2600(18)30096-1.
3
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.耐多药、广泛耐药和不可治愈结核病的流行病学、发病机制、传播、诊断及管理
Lancet Respir Med. 2017 Mar 15. doi: 10.1016/S2213-2600(17)30079-6.
4
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.治疗结核病新药物方案的优先级设定：一种流行病学模型
PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.
5
WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.世界卫生组织关于缩短耐多药结核病治疗疗程的建议。
Lancet. 2016 Jun 18;387(10037):2486-7. doi: 10.1016/S0140-6736(16)30729-2.
6
The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.南非用于初治活动性结核病一线治疗的四个月疗程的影响及成本效益
PLoS One. 2015 Dec 30;10(12):e0145796. doi: 10.1371/journal.pone.0145796. eCollection 2015.

Would pan-tuberculosis treatment regimens be cost-effective?

作者信息

Kendall Emily A, Brigden Grania, Lienhardt Christian, Dowdy David W

机构信息

1550 Orleans Street, Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21230, USA.

The International Union Against TB and Lung Disease, Geneva, Switzerland.

出版信息

Lancet Respir Med. 2018 Jul;6(7):486-488. doi: 10.1016/S2213-2600(18)30197-8. Epub 2018 May 31.

DOI:10.1016/S2213-2600(18)30197-8
PMID:29859919
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6191652/
Abstract
摘要